-
-
-
-
-
-
-
Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards
-
-
-
-
-
-
-
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
-
-
-
-
-
-
-
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy
-
-
-
-
-
-
-
Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results
-
-
-
-
-
-
-
Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules
-
-
-
-
-
-
-
Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

